drugs that could be used in conjunction with surgery to treat this debilitating neurological disease.
receptor may be new therapeutic targets for developing 1 the fetal mice. These results suggest that LPA and its LPA receptor antagonist blocked the ability of LPA to induce hydrocephalus in 1 came with their demonstration that an LPA receptor, they were unable to induce hydrocephalus. The key finding 1 experiments with fetal mice lacking the LPA receptor by these cells. When the researchers repeated their 1 this mislocalization depended on expression of the LPA resulted in altered adhesion and mislocalization of neural progenitor cells along the surface of the ventricles and that LPA how an increase in LPA might affect cortical development and lead to hydrocephalus. They show that injection of cerebral ventricles of fetal mice in utero, the mice did indeed develop severe hydrocephalus. The authors wondered might be involved in the development of hydrocephalus. When they injected a solution containing LPA into the investigators reasoned that LPA, a blood-borne lipid that is known to be important for the developing cerebral cortex, hydrocephalus, with animals displaying enlarged heads, dilated ventricles, and thinning of the cortex. The different time points. Injection of serum or plasma but not red blood cells induced CSF accumulation and utero at 13.5 days of gestation. The animals were then assessed prenatally 1 or 5 days later or postnatally at several
The authors injected serum, plasma, or red blood cells into the cerebral ventricles of the brains of fetal mice in hydrocephalus does not develop in fetal mice.
by a receptor antagonist, that 1 hydrocephalus and show that when LPA is prevented from binding to its receptor LPA they developed. They identify a blood-borne lipid called lysophosphatidic acid (LPA) as a potential cause of set out to investigate which factors in blood trigger hydrocephalus using an in vivo fetal mouse model that et al. Yung ventricles, but this approach only relieves intracranial pressure and does not solve the root cause of the disorder. cerebral The most common treatment is surgical insertion of an intraventricular shunt that drains excess CSF from the fetus, suggesting that factors or components in blood may trigger development of this severe neurological disorder.
in 1500 live births. One apparent cause of hydrocephalus is bleeding into the cerebral ventricles or brain tissue of the 1 ventricles during fetal development and is one of the most common neurological disorders of newborns, occurring in
INTRODUCTION
Fetal hydrocephalus (FH) is a life-threatening condition resulting from excessive accumulation of cerebrospinal fluid (CSF) that occurs in 1 in 1500 newborns annually (1) . FH is treated by palliative shunt placement or ventriculostomy to drain excess fluid from the brain; other neurosurgical and pharmacological interventions have proven suboptimal (2) . There is some evidence for genetic contributions to rare forms of hydrocephalus, but most cases are sporadic with an unclear etiology (3) .
Intriguing observations have linked FH to prenatal bleeding events, such as intracranial or germinal matrix hemorrhage, which could produce pathophysiological exposure to blood derivatives like plasma and serum (1) . This suggests that factors associated with blood could contribute to FH (2) . Furthermore, FH has been associated with alterations in neural cell fate in the cerebral cortex, suggesting that intracranial hemorrhage and FH may share a common pathogenic process (3) . A molecule found in blood and the developing cerebral cortex is the lipid lysophosphatidic acid (LPA). LPA is produced through multiple biochemical pathways (4) and has numerous biological properties that are mediated through a family of six known heterotrimeric guanosine 5′-triphosphate-binding protein (G protein)-coupled receptors, LPA 1 to LPA 6 (5, 6) . LPA is also a normal component of blood and blood derivatives such as plasma and serum. Human serum may have LPA concentrations exceeding 30 mM during clotting (4); this is from 5000-to more than 15,000-fold the EC 50 (median effective concentration) of its receptors as measured in neural progenitor cell assays (7) . Multiple LPA receptors are expressed in the embryonic cerebral cortex (8) . LPA receptor-dependent signaling influences a broad range of cellular processes that can alter the electrophysiological, cytoskeletal, morphological, antiapoptotic, and proliferative properties of neural progenitor cells (5) . Neural progenitor cells, such as radial glia, divide and give rise to postmitotic neural cells that form the mature cerebral cortex. Additionally, radial glia generate the ciliated ependymal cells that line the surface of the ventricles in the brain. LPA receptordependent effects can thus alter the overall organization of the embryonic cortex (9, 10) .
To assess whether exposure of the embryonic brain to prenatal blood, serum, or LPA may be implicated in FH, we developed an embryonic mouse model of FH. In this model, the brains of mouse embryos were exposed to blood components or to LPA and were analyzed pre-and postnatally for development of FH. We further investigated the role of LPA and its cognate receptor LPA 1 in the induction of FH and were able to block FH development in our model using a small molecule that inhibits LPA 1 receptor signaling.
RESULTS
Serum or plasma exposure induces FH Intracranial hemorrhage and blood clotting can expose the developing brain to a combination of red blood cells (RBCs), plasma, or serum. In our study, these components were isolated and delivered intraventricularly to the cerebral cortex of mouse embryos at embryonic day 13.5 (E13.5) (Fig. 1, A to C) . In this mouse model of FH, pregnant animals underwent laparotomy in which the uterine horns were accessed and the embryos were visualized by direct illumination. Solutions were delivered through the uterine wall and fetal cranium into the lateral ventricles (LVs) of the fetal brain as a single bolus dose. The mice were analyzed at different stages of fetal development and postnatally for the development of FH. Fetal delivery of serum or plasma induced development of FH, with postnatal animals displaying characteristic dome-shaped, enlarged heads, dilated LVs, and thinning of the cortex (Fig. 1, E and H). Cohorts exposed prenatally to serum or plasma developed hydrocephalus in 25 and 50% of animals ( Fig. 1N ; n = 12 and n = 6, respectively), whereas uninjected animals or those exposed to vehicle or injection of RBCs did not (Fig. 1, D , G, and N; n = 19). In addition, early cortical wall disruption appeared in wild-type animals after 24 hours of exposure to serum or plasma but not to fig. S1 , A to F). These data indicated that hydrocephalus could be initiated by hemorrhagic components, which is consistent with epidemiological data (1) and an animal model of intracranial bleeding that reported the development of ventricular dilation and hydrocephalus (11) . These data also demonstrated that neither RBCs nor an acute increase in ventricular fluid volume produced by vehicle injection was sufficient to produce sustained ventricular dilation or FH (Fig. 1, D and N) . This supports the possibility that a serum or plasma factor or factors are capable of initiating hydrocephalus.
LPA exposure induces histological changes and FH LPA is a bioactive factor present in both plasma and serum that can alter the organization of the embryonic cerebral cortex ex vivo (9) , and its activities might contribute to the induction of FH. The effects of embryonic LPA exposure were examined in wild-type embryos at E13.5, an age when neural progenitor cells respond robustly to LPA (7, 9) , and at later developmental ages. Markedly, LPA-injected animals developed severe hydrocephalus 100% of the time (Fig. 1, F , H, and N; n = 16) that was clearly visible by postnatal day 10 (P10) based on ventricular dilation and cortical thinning (Fig. 1, H and J). Hydrocephalus was not observed in vehicle-injected (n = 19) or noninjected littermates (n = 10) (Fig. 1, D , G, I, and N). Hydrocephalic animals showed progressively increasing head width (interaural distance, Fig.  1K ), head height (mandibular-rostral distance, Fig. 1L ), and body weight loss (Fig. 1M) , although there was no significant difference in the anterior-posterior dimension (fronto-occipital distance) ( fig. S3A ). In addition, these hydrocephalic animals displayed dome-shaped heads (Fig. 1F ) and altered subcortical structures such as caudate, putamen, and corpus callosum (Fig. 1H) . Hydrocephalic animals survived from 2 to 6 weeks after birth ( fig. S3B ).
Histological alterations found in mouse models and clinical cases of human hydrocephalus (table S1) were observed after exposure to LPA, but not vehicle control. Lateral ventricular size was bilaterally increased after LPA exposure compared to vehicle control (Fig. 2 , A to C, and fig. S4 , A to L). In addition, the apical ventricular surface (which comprises neural progenitor cells at this age) was disrupted and showed protrusions into the LVs (Fig. 2, D to F) . In severely disrupted areas, rounded cell clusters appeared to detach from the ventricular surface (Fig. 2, G to I ). These clusters were immunoreactive for nestin (a neural progenitor cell marker), incorporated bromodeoxyuridine (BrdU), and expressed Lpar1 detected by in situ hybridization ( fig. S5 , A to I). Lpar1 expression is present in the ventricular zone (VZ) of the brain, confirming that the clusters were of VZ origin. Furthermore, the formation of neurorosettes-abnormal, radially oriented cells-within the VZ was observed (Fig. 2, J to L) . Finally, other areas of the cerebroventricular system were also affected, for example, the third ventricle, another CSF-filled cavity located caudal and medial to the LVs. Cells from the third ventricular wall protruded into the CSFfilled ventricle, consistent with partial third ventricle occlusion (Fig. 2 , M to Q). This abnormal localization of cells (heterotopia) is consistent with heterotopia observed in FH patients (12) . One mechanism that could contribute to these diverse pathological findings is altered adhesion of neural progenitor cells induced by LPA signaling that may result in abnormal cell migration and positioning in the fetal mouse brain (13) .
LPA exposure disrupts neural progenitor cell function Cell adhesion molecules required for the formation of adherens junctions between cells help to maintain the luminal integrity of the cere- (table S1) . LPA has been shown to both increase and decrease cell-cell contacts mediated by N-cadherin in a cell type-and receptor subtype-specific manner (13, 21) . This suggests that modulation of LPA signaling may affect the integrity of the brain's ventricles. The apical surface of the LVs was examined for N-cadherin expression that was found to be discontinuous in LPA-exposed mouse embryos but not vehicle controltreated embryos (Fig. 3, A and B). Consistent with N-cadherin's function in maintaining the correct attachment of dividing neural progenitor cells to the apical surface (15), LPA-injected embryos showed a marked increase in the incorrect upward and basal positioning of mitotic cells (Fig. 3 , C, D, and I; P = 0.002, unpaired t test). In addition, clusters of neural progenitor cell spheres (Fig. 2 , H and I) (29 ± 7.1 per LPA-exposed embryo) were observed floating within the ventricles of LPA-treated embryos. This is consistent with the finding of neural progenitor cells in the CSF of newborns with posthemorrhagic hydrocephalus (22) . A cause of hydrocephalus is loss of cilia or ciliary function on the ependymal cells lining the ventricular surface, where the cilia are thought to reduce the flow of CSF along the ventricle walls (23) (24) (25) (26) (27) (28) (29) (30) . Ependymal cells differentiate during mid to late neurogenesis in the developing brain and mature in early postnatal life to form a single multiciliated cell layer that can be identified by immunostaining for S100b and acetylated a-tubulin (31). After exposure of mouse embryos to LPA, alterations in ependymal cells were observed at P4. Partial loss of mature ependymal cells, identified by the co-absence of S100b and acetylated a-tubulin immunoreactivities, manifested as discrete regions lacking cells (Fig. 3 , E and F, and videos S1 and S2). These results are consistent with the reported loss, or denudation, of ependymal cells in both clinical cases and mouse models of FH (25, 29) .
LPA activates Rho and Rac in the embryonic cortex LPA receptors, particularly LPA 1 , are powerful activators of the small guanosine triphosphatase (GTPase) Rho (32), as well as the closely related GTPase Rac (33) . To determine the possible involvement of these pathways in LPA-induced FH, we examined Rho and Rac signaling using ex vivo cerebral cortical cultures grown in the presence or absence of LPA, followed by measurements using an enzyme-linked immunosorbent assay (ELISA). There was activation of both prototypical members RhoA (n = 6 pairs; P = 0.04, paired t test) and Rac1 (n = 6 pairs; P = 0.01, paired t test) in the embryonic cortex (7) after LPA stimulation ( Serum, plasma, and LPA induce LPA receptor-dependent FH Several blood-related factors such as transforming growth factor-b (TGF-b) and vascular endothelial growth factor (VEGF) have been reported to be elevated in CSF from hydrocephalic individuals (34) . When administered to young mice, these growth factors can cause ventricular dilation and hydrocephalus (35) . This raised the possibility that factors in addition to LPA, present in plasma and serum, could be responsible for producing FH and associated histological changes observed in this mouse model. To address this question, we injected mouse embryos having genetic deletion of specific LPA receptors with plasma, serum, or LPA and then assessed them pre-and postnatally. Based on gene expression studies, LPA 1 and LPA 2 receptors were expressed in the neural progenitor cell population of the VZ (figs. S7, A to L, and S8, A and B) and are coupled to the same G proteins that mediate LPA signaling (9, 36) . To minimize receptor compensation, we examined LPA 1 mice were subsequently used as controls and compared to doublenull mutant animals. Both plasma and serum induced cortical disruption that was abrogated in double-null mutant mice ( fig. S1 , A, B, D, and E). Critically, LPA's ability to induce FH and associated histological changes (tables S1 and S2) was strongly dependent on the expression of LPA 1 . In LPA 1 +/− LPA 2 −/− control animals exposed to LPA, FH showed complete penetrance (n = 10, 100%). In contrast, FH was reduced to about 10% in double-null mutant mice (n = 9, 11%) (Fig. 4K, fig. S9 , A to G, and table S1). The rare occurrence of FH in double-null mutant animals likely reflects contributions by one or more of the remaining four LPA receptors rescuing the double-null phenotype. These data suggest that FH, along with associated histological changes, induced by plasma, serum, or LPA exposure, is primarily dependent on the LPA 1 receptor.
Pharmacological LPA 1 blockade prevents FH and histological changes The identification of LPA receptor signaling as a potential initiating cause of FH suggested that pharmacological modulation of LPA receptors could influence the development of FH. Ki16425, a receptor antagonist with proven specificity against LPA 1 and LPA 3 (37) , was intraventricularly injected before LPA exposure. Available genetic and expression data did not support a role for LPA 3 in LPA-induced FH (38, 39) . Mouse embryos that were treated with vehicle followed by LPA showed similar cortical defects compared to mice treated with LPA only (n = 5) (Fig. 5, A and B) . In contrast, mouse embryos treated with Ki16425 followed by LPA showed a marked reduction in FH and related histological changes (n = 5) (Fig. 5, C , D, and G to I). In the control, treatment with Ki16425 followed by vehicle produced no such effects (n = 4) (Fig. 5, E to I ). These data demonstrate that pharmacological intervention targeting LPA receptors, particularly LPA 1 , could attenuate development of LPA-induced FH. These pharmacological studies on wild-type mice independently support the results obtained with the receptor-null mice and also eliminate the possibility that constitutive receptor deletion produces developmental artifacts that somehow prevent FH.
DISCUSSION
Here, we generated a new mouse model of FH through exposure of the brains of mouse embryos to blood components or the bioactive lipid LPA. Using this model, we showed that the histological consequences of FH occurred mainly through the LPA 1 receptor signaling pathway in neural progenitor cells within the developing cerebral cortex and that these effects could be blocked by either genetic deletion or pharmacological inhibition of this G protein-coupled receptor. We propose that LPA 1 receptor signaling is a molecular mechanism that may account for the epidemiological observations linking prenatal bleeding and FH (Fig. 6 ). Intracranial hemorrhage into the germinal matrix (or VZ layer) of the developing cerebral cortex and into CSF results in abnormally high concentrations of LPA that aberrantly activate LPA receptors expressed by neural progenitor cells. This in turn activates downstream intracellular signaling components to produce disorganization and thinning of cortical layers and ultimately FH (Fig. 6 ). Additional histological consequences of aberrant LPA receptor activation include neural progenitor cell cluster formation, third ventricle occlusion, and loss of cilia along the lateral ventricular walls. How these changes relate precisely to each other remains to be determined. Additional endpoints such as CSF overproduction and elevated intracranial pressure remain to be tested in this model, particularly as they relate to 
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The effects of antagonist alone were assessed with Ki16425 followed by vehicle, and then embryonic and postnatal assessment for hydrocephalus. Apical protrusions of ventricular cell clusters (A, arrows) were observed 24 hours later in embryos injected with vehicle and then LPA but not in embryos injected with drug and then LPA, or drug then vehicle (C and E). Scale bar, 100 mm. (G to I) Quantitative assessments measured head dimensions in positive controls and animals exposed to drug. Positive controls (animals exposed to vehicle then LPA) showed the expected changes in head dimensions and hydrocephalus (black lines, G to I). In each set of head dimension measurements, statistically significant increases were observed in vehicle + LPA-treated mice compared with the normal head measurements obtained with drug + LPA-treated animals (red and blue lines, G to I). No statistically significant changes were observed between drug and vehicle (blue line)-injected and drug and LPA (red line)-injected embryos (n ≥ 3 embryos per condition; average ± SD; P > 0.05, unpaired t test; see table S3).
these histological changes. Aberrant activation of LPA receptors may explain the diverse histological presentation reported for human FH, and is consistent with other FH-relevant animal models (table S1) . Based on genetic and pharmacological studies, the primary receptor mediating these effects is LPA 1 with comparatively minor contributions by other LPA receptor subtypes. Although other contributory factors in addition to LPA may be present in blood, genetic deletion of LPA receptors prevented plasma and serum from inducing FH. This suggests a primary role for receptor-mediated LPA signaling in the development of FH. A variety of gene mutations in animals have been reported to result in FH. LPA signaling has been documented to interface with many of these genes and their activated pathways. FH has been linked to cadherins (15, 20) , adhesion molecules that are altered by LPA signaling (40) . Loss of myosin IIB and IXa results in hydrocephalus, consistent with participation of myosin pathways in the developing central nervous system (CNS) and their modulation by LPA signaling (41) . The small GTPase Rho that is activated by LPA (13, 36) has also been linked to FH (18) . We showed that this signaling component, along with its partner Rac, was activated in the cerebral cortex of mouse embryos exposed to LPA. Through its presence in blood, LPA thus has the potential to modulate one or more molecular pathways that have been linked to FH.
Genetic deletions in cilia-related proteins, such as Polaris (Tg737), Stumpy, or Hydin (24, 26, 27, 30) , or mutations leading to primary ciliary dyskinesia (42) , have been implicated in FH, suggesting that loss of cilia may contribute to the development of this disorder. The loss of cilia observed in the current study, which appears to result from disruption of neural progenitor cells, is consistent with altered cell fate whereby ciliated ependymal cells are reduced due to death of neural progenitor cells or their differentiation into nonciliated cell types (29) . This phenomenon of ciliary loss complements previous genetic data and connects the action of LPA (through pathological exposure of the cerebral cortex to blood) to dysfunction of neural progenitor cells and loss of ciliated ependymal cells in FH.
In previous work, aberrant activation of LPA signaling in ex vivo organotypic cerebral cortical cultures of fetal brain produced major disruption of neural progenitor cell function and gross disorganization of the cortex including abnormal cortical folding resembling polygyrations (9) . This ex vivo method relied on the dissection, separation, and culture of intact cortical hemispheres in the continuous presence of LPA. However, the limited survival time of the cultures (~20 hours) prevented multiday and prenatal versus postnatal comparisons. In contrast, we were able to recapitulate ventricular dilation and other histological changes observed in human FH using our in vivo model of FH reported here (9) . Both in vivo and ex vivo data implicate displacement of neural progenitor cells as a causative factor in FH (Fig. 3) (9) . Contrasting effects observed between the in vivo and the ex vivo studies can be explained by the existence of additional elements such as growth factors and cytokines in our in vivo system that are known to influence neurogenesis and formation of the cerebral cortex (43, 44) . Blockage of CSF flow (which was not duplicated in ex vivo cultures) may also contribute to FH (45) . Other differences between the in vivo and ex vivo studies include localized ventricular administration of a single bolus of LPA versus whole-brain exposure to LPA, respectively. Despite these differences, the acute disruption of mitotic neural progenitor cells and the dependence of this disruption on the LPA 1 receptor were conserved between the in vivo and ex vivo studies. Intriguingly, some hydrocephalic patients have also been reported to exhibit cortical polygyrations, consistent with the effects seen during prolonged ex vivo cortical exposure to LPA (46) .
The cellular alterations that resulted in dilated ventricles, neurorosettes, ventricular disruption and occlusion, and cilia loss are likely due to the direct effects of LPA receptor activation on neural progenitor cells in the VZ rather than on secondary effects that result from hemorrhage or the actions of other factors in blood. First, intraventricular exposure to plasma or serum can induce FH in some but not all exposed mouse embryos. However, FH was absent in LPA 1 −/− LPA 2 −/− double-null mice, indicating that non-LPA blood products, if present, played a minor role in inducing FH. Second, at the age that mouse embryos were exposed to LPA (E13.5), the LPA 1 receptor is expressed primarily by neural progenitor cells in the VZ (fig. S7 , A to L) (7). The observed histological defects were inconsistent with primary disruption involving the diffuse organization of blood vessels throughout the cerebral cortical wall (38, 47) , which should have produced effects throughout the cortex and noncortical neuraxis where blood vessels are also present. The LPA 1 receptor is also expressed in the superficial marginal zone (future layer 1 of the cortex) and developing meninges at E13.5 ( fig. S7, E Several potential limitations of this in vivo model should be mentioned. First, the progression of cortical brain development in mice is similar but not identical to the extended course in humans. Second, the spatiotemporal extent of intracranial hemorrhage and severity of exposure to blood in fetuses is not well delineated; thus, this bolus exposure model likely only approximates the spectrum of pathological insults during development of human FH. Future translational studies focused on patient samples may help to refine this animal model. Although this study focused on a preventative strategy in which the LPA 1 receptor antagonist was delivered before LPA exposure, there was likely to be considerable temporal overlap between exposure of the mouse embryonic brain to both LPA and antagonist. Furthermore, we note that neural progenitor cell loss and ventricular dilation occurred prenatally but progressed to severe hydrocephalus only at neonatal ages, indicating that FH progression may occur in stages, as reported in humans (25) . This underscores the feasibility of a therapeutic strategy whereby early prenatal ventricular dilation associated with intracranial hemorrhage could be ameliorated by short-term LPA receptor modulators without affecting LPA-mediated normal cortical development but reducing or preventing hydrocephalus.
The identification of LPA signaling in the initiation of FH is consistent with a diverse range of reported risk factors that share FH as a common endpoint. Reported risk factors include bleeding, hypoxia, infection, meningitis, and brain tumors, all of which have been associated with increased LPA signaling (48) (49) (50) (51) . The disparate histological phenomena associated with human FH (table S1) can be reproduced by exposure of embryonic mouse brain to LPA, supporting a shared molecular mechanism in both mice and humans. The ability to prevent FH by pharmacologically blocking LPA signaling suggests that LPA and its LPA 1 receptor have potential as therapeutic targets for treating at least some forms of FH. Whether other forms of FH are amenable to this treatment strategy requires further study. Finally, it is notable that a host of developmentally linked disorders including cerebral palsy (52) , schizophrenia (53) , and autism (54) have also been epidemiologically associated with prenatal bleeding, suggesting that future studies should investigate a potential connection between aberrant LPA signaling and these neurodevelopmental disorders.
MATERIALS AND METHODS
Injection solutions LPA (18:1) (Avanti Polar Lipids) solution [10 and 20 mM in Hanks' balanced salt solution (HBSS)] was prepared fresh just before use by ultrasonication in a water bath (Branson) for 15 min at 22°C. Whole blood was obtained from female adult mice by cardiac puncture collection and clotted for 1 hour on ice. The clot was manually removed, and the remaining solution was spun down at 2000 rpm for 20 min at 4°C. The top "serum" and bottom "red blood cell" (washed and resuspended in HBSS) fractions were collected by centrifugation separation. The "plasma" fraction was obtained as previously described (11) . Ki16425 (Kirin Brewery, 1 mM final concentration in HBSS) was prepared for intraventricular injections. BrdU solution was prepared (Sigma, 100 mg/kg final concentration) for intraperitoneal injection.
Injections
All procedures followed proper animal use and care guidelines that were approved by the Institutional Animal Care and Use Committee at The Scripps Research Institute. In utero injections of 3 ml of vehicle (HBSS), plasma, serum, RBC, or LPA solutions into embryonic cortices were performed on pentobarbital anesthetized (Nembutal, 50 mg/kg), timed-pregnant dams at E13.5. Embryos were examined after 1 day (E14.5), 5 days (E18.5), or postnatally at P4, P10, P21, and 4 weeks. For Ki16425 intervention experiments, E13.5 embryonic cortices were injected with 1.5 ml of Ki16425, exposed for 15 min, and then subsequently injected ipsilaterally with 1.5 ml of LPA solution (20 mH), sutured, and examined 1 day later. For postnatal assessment, pups were allowed to be birthed naturally. Because uterine positional order was lost during delivery, all embryos within each litter were injected with identical ligands. Pharmacological studies were performed with 1.5 ml of each ligand (LPA at double concentration) to maintain consistent injection volumes across studies.
Histology
Pregnant dams were intraperitoneally anesthetized with pentobarbital (50 mg/kg), during which the embryos were collected whole by surgical dissection, decapitated, and heads fixed in formalin-alcohol-acetic acid solution (FAA) or 4% paraformaldehyde (PFA). Subsequently, the anesthetized dams were killed by cervical dislocation. Naturally birthed pups were anesthetized with pentobarbital and transcardially perfused with FAA or PFA. Their brains were immersion-fixed with FAA or PFA, paraffinized with an automated processor (Sakura), and embedded in paraffin. The tissue was sectioned (6-to 10-mm thickness), dewaxed, and stained with hematoxylin and eosin. Only healthy embryos with observable heartbeats were analyzed (≥95% injected).
Immunofluorescence Brains preserved in FAA or PFA were examined. Sucrose cryoprotected/ frozen heads fixed in PFA were sectioned (16 mm), blocked with speciesappropriate serum, and immunolabeled. Paraffin sections (6 to 10 mm) were additionally dewaxed and processed through sodium citrate buffer (10 mM, 0.05% Tween 20, pH 6.0) antigen retrieval before antibody staining. Antibodies specific for the following antigens were used in overnight staining at 4°C: nestin (BD Biosciences, mouse, 1:400), b-III-tubulin (Covance, mouse, 1:1000), phosphorylated histone H3 (Ser 10 ) (Millipore, rabbit, 1:1000), S100b (Abcam, rabbit, 1:500), acetylated a-tubulin (Sigma, mouse, 1:1000), N-cadherin (Calbiochem, rabbit, 1:200), and BrdU (Roche, rat, 1:50). Mouse-, rabbit-, or ratspecific secondary antibodies conjugated with Alexa Fluor 488 or Cy3 (Invitrogen or Jackson Immunoresearch, donkey, 1:1000) were used for visualization. Nuclei were counterstained with 4′,6-diamidino-2-phenylindole (DAPI, Sigma).
Image acquisition and quantification
Epifluorescence images were acquired on a Zeiss Imager 1D microscope (AxioVision 4.7.2 software) with appropriate fluorescence filters. Confocal images were acquired on an Olympus FluoView 500 laser scanning microscope with appropriate lasers and optimized Z steps, sequential channel acquisition, and Kalman filtering of 4. Confocal image stacks were analyzed and reconstructed into videos with MetaMorph software (version 7, Molecular Devices). Images and manual counting were analyzed by investigators blinded as to sample identity. Inadvertent loss of blinding occurred when differences between control and experimental samples were markedly obvious but would not have altered the basic interpretation and results of this study. Photoshop adjustments (version 11.0, Adobe) were strictly limited to light level and contrast enhancement for visual aesthetics that did not change data interpretation.
Statistical analysis
Statistical analyses were performed with Prism software (version 5, GraphPad). Normality of data distribution was tested with the F test for unequal variance. Normally distributed data were analyzed with unpaired or paired Student's t test when comparing between two data groups. Nonnormally distributed data were analyzed with the nonparametric Mann-Whitney test and Kruskal-Wallis and Dunnett's post hoc tests when comparing between two and three data groups, respectively. Data were expressed as average ± SD and considered significant if tests indicated P ≤ 0.05.
Head size measurement
Increased head circumference, clinically used as a standard indicator of hydrocephalus, is typically measured with a cloth tape above the ears, but is not technically feasible nor accurately reproducible in early postnatal mice because of small size and incomplete skull calcification. Instead, an electronic caliper (C-master digital gauge) was used to perform three unidimensional measurements: interaural distance (ear to ear), mandibular-rostral distance (jaw to top of the head), and frontooccipital distance (forehead to back of the head). Individual measurements were performed in triplicate and averaged. Measurements were performed at P3, P6, P10, P12, P15, P18, P20, P25, and P30. Postnatal animals were tattooed for individual identification.
Ventricle area measurement
Paraffinized embryo heads in coronal presentation were serially cut (10-mm thickness). Sections at 100-mm intervals from anterior to posterior were imaged. LVs were manually traced, and area sizes were calculated automatically with AxioVision software (version 4.7.2, Carl Zeiss) and tabulated. At least six sections were measured per embryo.
Construction and labeling of in situ hybridization probes Mouse Lpar1 exon 3 was amplified by polymerase chain reaction (PCR) from a bacterial artificial chromosome (BAC) template with Pfx50 DNA polymerase (Invitrogen) with the following primers: A1Ex3For, 5′-TTCACAGCCATGAACGAACAAC-3′ and A1Ex3Rev, 5′-ACCAAGCACAATGACCACAGTC-3′, and tailed with Taq polymerase. The 748-base pair product was then isolated with the QIAEX II DNA isolation kit (Qiagen), cloned into the pGem-T Easy T vector (Promega), and linearized with appropriate restriction enzymes. Digoxigenin (DIG)-labeled sense and antisense runoff transcripts were transcribed with DIG labeling mix (Roche) and SP6 and T7 RNA polymerases (Roche), respectively. DIG-labeled sense and antisense mouse Lpar2 probes were prepared as previously described (38) .
In situ hybridization Embryo heads were examined for Lpar1 and Lpar2 expression as previously described (7) . Paraffin sections were dewaxed and rehydrated with diethyl pyrocarbonate (DEPC)-treated solutions before hybridization. All probes were hybridized at 65°C.
RhoA and Rac1 activation ELISA assay Fresh embryonic cortical hemispheres were dissected out in ice-cold Opti-MEM (Invitrogen). Matched hemispheres were cultured in media supplemented with 10 mM LPA and 0.1% fatty acid-free bovine serum albumin or without LPA, essentially as previously described (9, 55) . LPA stimulation was terminated in ice-cold Opti-MEM without LPA. The cortical wall was dissected away from the ganglionic eminences, triturated in lysis buffer, and snap-frozen in liquid nitrogen. Activation of RhoA and Rac1 was measured with absorbance-or chemiluminescencebased G-LISA kits, respectively, according to the manufacturer's instructions (Cytoskeleton) with an EL800 microplate reader and a SynergyMX luminometer (Bio-Tek). Antibody concentrations were optimized for machine sensitivity. Statistically significant but modest activation levels likely reflect the absence of serum starvation, used to approximate in vivo conditions, along with the influence of other endogenous signaling pathways that increase the basal activation of Rho and Rac.
LPA measurements
The LPA extraction method was adapted with some modification (56) . Briefly, 50 ml of tissue homogenate [final concentration (fresh tissue) 200 to 400 mg/ml] was used for each sample. Methanol/HCl (187.5 ml, 10:1 mixture) and 625 ml of methyl-tert-butyl ether (MTBE) were added to each sample and incubated on a nutator at 22°C for 1 hour. Distilled water (157 ml) was then added to the mixture, incubated for 10 min, and phase-separated by centrifugation at 13,000 rpm for 10 min. The initial organic phase was collected, whereas the aqueous phase was reextracted with 250 ml of MTBE/methanol/H 2 O (10:3:2.5 ratio). Both organic phases were combined and dried with a SpeedVac concentrator (Savant) and resuspended in 100 ml of methanol. Nonnatural 17:0 LPA (Avanti Polar Lipids) was added as an internal standard. The extracts were subjected to liquid chromatography-mass spectrometry (LC-MS) for LPA measurement at the TSRI Mass Spectrometry Core with an Agilent 6410 triple quad mass spectrometer coupled to an Agilent 1200lc stack. Compounds were eluted with a mobile phase of H 2 O/ACN 90:10 with 10 mM NH 4 OAc (A) and ACN/H 2 O with 10 mM NH 4 OAc (B) at 0.2 ml/min. Agilent 300SB-C8 2.1 mm × 100 mm, 3.5 mm columns were used. The gradient was t = 0, 80:20 (A/B); t = 5, 50:50; t = 7, 25:75; t = 15, 0:100; t = 20, off. There was a 5-min reequilibration time between samples. The source was maintained at 350°C with a drying gas flow of 10 liters/hour, and data were collected in negative ion mode. The following transition states were monitored: on February 9, 2012 stm.sciencemag.org 
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